Calistoga Pharmaceuticals
Developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
€341m (Public information from Feb 2011)
Seattle Washington (HQ)
Authorizing premium user...